A new approach to treating heart failure
Official title: A novel strategy for heart failure therapeutics
Funded at University of Cincinnati · NIH-10997341 · Data updated 2026-11-12
This study is looking at a tiny molecule called miR-128 that seems to be higher in hearts that are not working well, to help us understand how it affects heart muscle cells and find new ways to treat heart failure, which could lead to better options for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | December 15, 2023 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $481,436 |
| NIH project number | 5R01HL168464-02 |
| Project ID | NIH-10997341 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with heart failure or those at risk of developing heart failure due to cardiac dysfunction.
✕Less likely to help
Patients with heart conditions unrelated to heart failure or those who do not have any cardiac issues may not benefit from this research.
What this research studies
This research investigates the mechanisms behind heart failure, focusing on a specific microRNA (miR-128) that is found to be elevated in failing hearts. By understanding how this microRNA contributes to heart muscle cell changes, the research aims to identify new therapeutic strategies to prevent the progression of heart failure. The study utilizes advanced techniques like next-generation sequencing to explore the genetic factors involved in heart function deterioration. Patients may benefit from insights that could lead to innovative treatments targeting the underlying causes of heart failure.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve heart function and quality of life for patients with heart failure.
How similar studies have gone: Other research has shown promise in targeting microRNAs for heart disease treatment, indicating that this approach could be a viable strategy.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Wang, Yigang — University of Cincinnati
- Study coordinator: Wang, Yigang
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.